Results 1 to 10 of about 2,347,326 (232)

Diffuse Large B-Cell Lymphoma

New England Journal of Medicine, 2021
Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease, or both and require therapy ...
Raynell, Lang, M John, Gill
openaire   +3 more sources

B-cell lymphoma, unclassifiable, intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma

Терапевтический архив, 2015
B-cell lymphoma that is unclassifiable and intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt’s lymphoma (BL) — (UBL) is an aggressive lymphoma that has simultaneously morphological, immunophenotypical, and cytogenetic signs of both ...
E A Baryakh, A E Misyurina, A M Kovrigina, V A Misyurin, S K Kravchenko   +4 more
doaj   +3 more sources

Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation

Haematologica, 2022
The sole distinguishing feature of follicular lymphoma grade 3B and diffuse large B-cell lymphoma is the growth pattern assessed by histopathology. Diffuse growth defines diffuse large B-cell lymphoma but the clinical relevance of this finding when ...
Karoline Koch, Julia Richter, Christoph Hanel, Andreas Huttmann, Ulrich Duhrsen, Wolfram Klapper   +5 more
doaj   +1 more source

Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2021
High-grade B-cell lymphoma, an aggressive form of Non-Hodgkin’s Lymphoma, is known as a double or triple hit lymphoma based on the presence of MYC and BCL2 without or with BCL6 genetic rearrangements, respectively. It carries a poorer prognosis, compared
NIKITA SAMPATHIRAO, Indirani Muthukrishnan, Ann Kurian, Jaykanth Amalchandran, Asra Patel, shema mathew, Shelley Simon   +6 more
doaj   +1 more source

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

New England Journal of Medicine, 2021
BACKGROUND The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor.
F. Locke, D. Miklos, C. Jacobson, M. Perales, M. Kersten, O. Oluwole, A. Ghobadi, A. Rapoport, J. Mcguirk, J. Pagel, J. Muñoz, U. Farooq, T. van Meerten, P. Reagan, A. Sureda, I. Flinn, P. Vandenberghe, K. Song, M. Dickinson, M. Minnema, P. Riedell, L. Leslie, S. Chaganti, Yin Yang, S. Filosto, J. Shah, M. Schupp, C. To, P. Cheng, L. Gordon, J. Westin   +30 more
semanticscholar   +1 more source

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2021
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP.
H. Tilly, F. Morschhauser, L. Sehn, J. Friedberg, M. Trněný, J. Sharman, C. Herbaux, J. Burke, M. Matasar, S. Rai, K. Izutsu, N. Mehta-Shah, L. Obéric, A. Chauchet, W. Jurczak, Yuqin Song, R. Greil, Larysa Mykhalska, J. Bergua-Burgues, M. Cheung, A. Pinto, H. Shin, G. Hapgood, E. Munhoz, P. Abrisqueta, J. Gau, J. Hirata, Yanwen Jiang, M. Yan, Calvin Lee, C. Flowers, G. Salles   +31 more
semanticscholar   +1 more source

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
M. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, Shang-Ju Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Pérez-Callejo, L. Lundberg, J. Relf, M. Dixon, E. Clark, K. Humphrey, M. Hutchings   +20 more
semanticscholar   +1 more source

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Journal of Clinical Oncology, 2021
PURPOSE Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin
M. Hutchings, F. Morschhauser, G. Iacoboni, C. Carlo-Stella, F. Offner, A. Sureda, G. Salles, J. Martínez-López, M. Crump, D. Thomas, P. N. Morcos, C. Ferlini, Ann-Marie E. Bröske, A. Belousov, M. Bacac, N. Dimier, D. Carlile, L. Lundberg, D. Pérez-Callejo, P. Umaña, T. Moore, M. Weisser, M. Dickinson   +22 more
semanticscholar   +1 more source

Primary Testicular B-cell Lymphoma

Journal of Urological Surgery, 2015
Primary testicular lymphoma constitutes only 1-7% of all testicular neoplasms and less than 1% of all non-Hodgkin lymphoma. We report a 69-year-old man who presented with a painful right testicular mass. Treatment modalities consist of surgical excision,
Aykut Buğra Şentürk, Musa Ekici, Hamit Ersoy   +2 more
doaj   +1 more source

Morphological characterization of canine retrobulbar lymphoma [PDF]

Open Veterinary Journal, 2018
This report characterized seven cases of canine retrobulbar lymphoma that have been diagnosed during 2008 to 2014 by immunophenotyping of CD3 and Pax5. Classification of lymphoma were performed according to the revised WHO guidelines.
Natthanet Sritrakoon, Kannika Siripattarapravat, Phudit Maneesaay, Chidozie J. Amuzie, Aree Thayananuphat   +4 more
doaj   +1 more source